EXEL vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 14, 2026

EXEL

67.7
AI Score
VS
EXEL Wins

MRNA

57.2
AI Score

Investment Advisor Scores

EXEL

68score
Recommendation
BUY

MRNA

57score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric EXEL MRNA Winner
Forward P/E 17.8891 23.0415 EXEL
PEG Ratio 2.2685 0 Tie
Revenue Growth 10.0% 260.2% MRNA
Earnings Growth 43.6% -85.1% EXEL
Tradestie Score 67.7/100 57.2/100 EXEL
Profit Margin 35.1% -143.6% EXEL
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD EXEL

Frequently Asked Questions

Based on our detailed analysis, EXEL is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.